Thyroid Eye Disease Treatment Shows Positive Results in REVEAL-2 Clinical Trial

DDW2026! We are presenting two new analyses at DDW this year showcasing our latest findings on the importance of mucosal healing in patients with irritable bowel disease using real-world data from the Crohn's and Colitis Foundation. If you are attending > stop by 🧠 Poster 1: Sa1520 & Poster 2: Sa1521  This work represents an amazing team effort and huge thanks to my collaborators on continuing to drive this evidence space. #Research #DDW #DigestiveDiseaseWeek

#Breaking: We are excited to share positive results from our Phase III trials evaluating our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). For the more than 2.9 million people living with multiple sclerosis (MS) worldwide, this data brings our research and development strides into focus, representing a potential new approach to MS with comprehensive disease control. Learn more: http://spr.ly/6046BB8uD8

We are pleased to share that the latest WHO consolidated guidelines for the management of sickle-cell disease in children and adolescents reference Gazelle-Multispectral within the discussion of point-of-care testing technologies. We are encouraged to see continued global focus on expanding access to diagnostic technologies that can support earlier detection, disease management, and monitoring for patients living with sickle cell disease. https://lnkd.in/dvmW54Q8 Patti White Peter Galen Umut A. Gurkan Disclaimer: Gazelle products referenced are not available for sale in the United States.

Access to clear, trusted information is important when considering participating in a clinical trial – especially in rare kidney disease. NephCure has added PrisMN, a Phase 2 clinical trial for people living with pMN, to its Clinical Trial Finder.  🔗 For more information, visit: https://lnkd.in/d7PU72Hx    #RareKidneyDisease #PrimaryMembranousNephropathy #pMN #ClinicalTrials

US HCPs: #Myelofibrosis clinical trial endpoints have historically focused on some of the key clinical hallmarks of the disease including splenomegaly or cytokine-related symptoms. Learn more about the clinical trial endpoints in myelofibrosis at https://lnkd.in/dGb6zKUw. #BelieversinScience #Myelofibrosis

The way we think about endpoints in #myelofibrosis continues to evolve. For many years, clinical trials in MF have focused on spleen volume reduction and symptom improvement—outcomes that remain meaningful for patients. As our understanding of MF biology grows, the conversation is broadening to consider a wider range of disease outcomes. This resource brings together references and perspectives to support healthcare professionals in navigating these evolving endpoints and the questions they raise in clinical practice. Ultimately, it’s about continuing to build a more complete picture of benefit—both in how patients feel and how they do over time. #BelieversinScience

Join us in listening to the voices of chronic cough! We’re sharing real patient stories to raise awareness of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung diseases (non-IPF ILDs). Chronic cough is commonly reported in these patients, yet every experience is different. Explore their stories and learn more: https://ow.ly/r6uN50YUNt4 #VoicesofChronicCough

The burden of chronic cough often goes far beyond the cough itself for patients living with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung diseases (non-IPF ILDs). From having to stop working, to the physical pain that comes from coughing, to removing themselves from everyday activities like going out to dinner or to the movies, the toll cough has had on their lives is evident. Hearing firsthand from Steve, Renée, Theresa and Ron, their stories highlight just how broad the impact of chronic cough can be on patients and their families. Thank you to Steve, Renée, Theresa and Ron, for sharing their stories with us, along with so many others who continue to speak up and help others feel seen and heard. #ChronicCough #IPF #ILD #PatientVoice #VoicesofChronicCough #caring4cough

On May 13, our experts will unveil major insights into how RWD is changing the game for clinical trials and rare disease patients. Stay tuned!

Today at #ATS, we presented for the first time, data demonstrating that our investigational treatment for alpha-1 antitrypsin deficiency (#AATD) met all primary and key secondary endpoints. These findings reinforce our commitment to advancing innovation for people living with this rare disease. Read more: http://spkl.io/6043Ah1BB #Sanofi